- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02679924
A Slit Face Trial Using Micro-injections of Transparent Hyaluronic Acid Gel for Rejuvenation of the Cheek
February 27, 2017 updated by: Isabella Guiha
A Single Center, Prospective, Randomized, Sham Controlled, Double Blind, Split Face Trial Using Micro-injections of Transparent Hyaluronic Acid Gel (Restylane® Silk) for Rejuvenation of the Aging Cheek
Soft tissue augmentation with injectable hyaluronic acid (HA) is a well-established modality for the correction of facial volume loss, fat atrophy, fine lines, and wrinkles.
HA is a glycosaminoglycan that is composed of repeating D-glucuronic acid and D-N-acetylglucosamine disaccharide units.
Because HA is a natural and inert constituent of the dermis, it represents an ideal substance for soft tissue augmentation.
Current FDA-approved HA fillers are typically utilized to either directly target specific cutaneous rhytids or to restore overall contours by placement into fat pads or along bony structures that have remodeled with age.
Restylane® Silk is a transparent injectable HA gel that received FDA approval in June 2014 for use in the lips and peri-oral region.
Its unique synthesis results in smaller and finer particles that demonstrate significant hygroscopic properties and give rise to the potential for unique applications.
One such application concerns the concept of "skin boosting" whereby microaliquots of HA are placed into the skin to induce biophysical improvement in dermal characteristics (1).
Using this technique, a recent split-body study by Streker et al. demonstrated significant aesthetic improvements in face, hands and décolletage (2).
However, there have been no well-controlled studies with validated aesthetic outcomes utilizing Restylane® Silk in this fashion to date.
Because of the unique combination of ultra-fine product and high water-attracting capability, the investigators hypothesize that microinjections of Restylane® Silk can be used in a grid-like injection pattern for rejuvenation of the aging cheek.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This is a single center, prospective, randomized, sham-controlled, double-blind, split-face trial using micro-injections of Restylane® Silk for correction of mid to low cheek fine lines and wrinkles.
Twenty (20) subjects will be enrolled.
Each subject will receive Restylane® Silk to a defined area of mid to low cheek in a randomized blinded fashion with the contralateral cheek treated by sham injection.
The injections will be delivered intradermally 1mm in depth via multiple 0.02 cc microinjections distributed in a grid array pattern with 0.5 cm to 1 cm between each injection point over total treatment area.
The sham injections will be administered in identical fashion and will consist of sterile normal saline.
Following completion of injection treatment, manual massage will be applied to the full area to promote even distribution of the product.
The maximum amount of Restylane Silk to be used per treatments session/per cheek for balancing treatment is1cc (not to exceed a total of 3cc) per treated patient.
Three dimensional digital photography utilizing the Vectra 3D System (Canfield) will be utilized to document pre-treatment status, sites of injection, and post-treatment effect.
Subjects will be followed up at 1 week, 2 week, 4 week, day 90, and day 180 time points.
At the Day 180 time point, every subject will be given the option to receive touch up and balancing treatments to both cheeks.
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92121
- Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female in general good health age 18 or over.
- Mild to moderate static rhytids involving at least a 9 cm2 area of the mid to low cheeks.
- Must be willing to give and sign a HIPPA form, photo consent and informed consent form.
- Must be willing to comply with study dosing and complete the entire course of the study.
Female patients will be either of non-childbearing potential defined as:
- Having no uterus
- No menses for at least 12 months
- Bilateral tubal ligation Or;
(WOCBP) women of childbearing potential must agree to use an effective method of birth control during the course of the study, such as:
- Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device
- Intrauterine coil
- Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom)
- Abstinence (If practicing abstinence must agree to use barrier method described above (3) if becomes sexually active).
Vasectomized partner (must agree to use barrier method described above (3) if becomes sexually active with un-vasectomized).
- Negative urine pregnancy test results Baseline prior to study entry (if applicable)
Exclusion Criteria:
- Pregnant, planning pregnancy during the course of the study or breastfeeding
- Severe static rhytids to the mid to low cheeks
- Previous use of any form of soft tissue augmentation in the treatment area within the past 12 months
- Pre-existing medical or dermatologic condition in the treatment area that may affect the treatment or interpretation of treatment effect (at investigator discretion)
- Presence of tattoo and/or scar in the treatment area that in the investigators opinion would interfere with study assessments
- Use of oral/topical retinoids within 1 month of Baseline
- Previous use of botulinum toxins in the treatment area within the past 6 months
- Previous surgical procedure in the treatment area within the past 12 months
- Presence or evidence of any conditions that in the opinion of the investigator might impede the subject's ability to give consent or comply with protocol requirements.
- Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study
- History of non-compliance with clinical research protocols
- Ablative laser resurfacing to on their face within 12 months
- Non-ablative laser or light procedures to their face within the past 3 months
- Known allergy to Restylane® Silk or any of its constituents
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Restylane Silk
Micro-injections of Restylane® Silk Hyaluronic Acid filler for correction of mid to low cheek fine lines and wrinkles.
|
The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
Other Names:
|
Sham Comparator: Sham Comparator
Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
|
Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Wrinkling and Elastosis
Time Frame: month 6
|
Efficacy will be determined based on the difference between blinded evaluator assessment of Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale between Baseline and Month 6.
|
month 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Mitchel P Goldman, MD, DCLA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (Anticipated)
August 1, 2017
Study Completion (Anticipated)
September 1, 2017
Study Registration Dates
First Submitted
November 11, 2015
First Submitted That Met QC Criteria
February 8, 2016
First Posted (Estimate)
February 11, 2016
Study Record Updates
Last Update Posted (Actual)
March 1, 2017
Last Update Submitted That Met QC Criteria
February 27, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RS-2015-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Problem of Aging
-
Williams Center Plastic Surgery SpecialistsSanofiCompleted
-
Clinical Centre of SerbiaCompletedSmoking | Physical Activity | Gender | Problem of Aging
-
Universidade da CoruñaCenter on Information and Communication TechnologiesCompletedQuality of Life | Cognitive Impairment | Sleep | Aging | Age ProblemSpain
-
Brigham and Women's HospitalNational Institute on Aging (NIA)CompletedStroke | Problem of AgingUnited States
-
Hong Kong Baptist UniversitySun Yat-sen University; Nanjing Normal UniversityCompleted
-
Freeman-Sheldon Research Group, Inc.CompletedObesity | Gender | Problem of AgingUnited States
-
University Hospital, MontpellierTerminated
-
Brigham and Women's HospitalNational Institute on Aging (NIA)CompletedStroke | Problem of AgingUnited States
-
National University of SingaporeRecruitingAging | Age Problem | Age-related Cognitive Decline | Age-Related AtrophySingapore
-
Medical University of GdanskJagiellonian University; Medical University of Lodz; Medical University of Silesia and other collaboratorsUnknownHealthy Aging | Age Problem | Frailty Syndrome | Immunity Disorders | Health Care Utilization | Aging Disorder | Behaviors, HealthPoland
Clinical Trials on Hyaluronic Acid filler
-
Rejuva Medical AestheticsUnknownTear Trough Hollowing, Under Eye BagsUnited States
-
Medy-ToxCompletedPenile Enhancement | Penile Girth EnhancementKorea, Republic of
-
Vandeputte, Joan, M.D.Universitair Ziekenhuis BrusselCompleted
-
Dieter Manstein, MDCompletedLip | Lip Augmentation | Lip AgingUnited States
-
Marmur MedicalCompleted
-
Merz Pharmaceuticals GmbHCompleted
-
University of PennsylvaniaActive, not recruitingDermal Filler | RejuvenationUnited States
-
Alexandria UniversityRecruitingChanges in Facial Muscles Following Filler InjectionEgypt
-
Jared Jagdeo, MD, MSAllergan; VA Northern California Health Care System; East Bay Institute for Research...CompletedHIV Facial LipoatrophyUnited States
-
Merz North America, Inc.CompletedCorrection of Moderate to Severe Nasolabial Folds (NLFs)China